As of January 23, 2025, Phio Pharmaceuticals (PHIO) has a market cap of $10.939 million USD. According to our data, Phio Pharmaceuticals is ranked No.8831 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 23, 2025 | $10.94 M |
45.85%
|
Dec 31, 2024 | $7.50 M |
-73.68%
|
Dec 29, 2023 | $28.50 M |
-82.97%
|
Dec 30, 2022 | $0.17 B |
-62.80%
|
Dec 31, 2021 | $0.45 B |
-62.83%
|
Dec 31, 2020 | $1.21 B |
-71.40%
|
Dec 31, 2019 | $4.23 B |
-48.18%
|
Dec 31, 2018 | $8.17 B |
-94.06%
|
Dec 29, 2017 | $137.62 B |
-22.24%
|
Dec 30, 2016 | $176.97 B |
-81.28%
|
Dec 31, 2015 | $945.49 B |
-76.13%
|
Dec 31, 2014 | $3.960 T |
-44.83%
|
Dec 31, 2013 | $7.178 T |
28.89%
|
Dec 31, 2012 | $5.569 T |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Arrowhead Pharmaceuticals
ARWR
|
$2.45 B |
-0.000 M
|
USA
|
Alnylam Pharmaceuticals
ALNY
|
$34.38 B |
-0.000 M
|
USA
|
Ionis Pharmaceuticals
IONS
|
$5.13 B |
-0.000 M
|
USA
|
Sarepta Therapeutics
SRPT
|
$11.09 B |
0.000 M
|
USA
|
Moderna
MRNA
|
$14.82 B |
-0.000 M
|
USA
|
BioNTech
BNTX
|
$27.61 B |
0.000 M
|
Germany
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Beam Therapeutics
BEAM
|
$2.19 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
Market Cap | = | PHIO Stock Price | * | PHIO Shares Outstanding |
= | $2.29 | * | 4.78 M | |
= | $10.94 M |